Boston Scientific Acquires Valencia Technologies to Challenge Medtronic in Overactive Bladder Therapeutics
Valencia Technologies
Developer of Implantable Neurostimulation Devices
Source: Medical Device Business Review
On January 12, 2026, Boston Scientific announced that it had entered into a definitive agreement to acquire Valencia Technologies, an innovative company in the field of implantable tibial nerve stimulation (ITNS), at an undisclosed price.
This acquisition marks another major strategic move by Boston Scientific in the urology field, following its $3.7 billion acquisition of Axonics in 2024.
Valencia's core product, eCoin, isThe World's FirstFDA-Approved Implantable Tibial Nerve Stimulator: Its Revolutionary Design Breaks Through the Limitations of Traditional Therapies
Miniaturized Design:Coin-sized (25 mm in diameter), requires only outpatient implantation under local anesthesia, with a discreet appearance post-implantation
Smart Leadless Technology:Built-in battery and chip, continuously and stably releasing tibial nerve stimulation through a dome-shaped stimulation field, avoiding lead complications associated with traditional sacral nerve stimulators.
Clinical Validation:Key Trial Shows ≥50% Reduction in Urge Urinary Incontinence Episodes in 68% of Patients, with Long-Term Safety Confirmed
Differentiated Advantages:Compared with sacral nerve stimulators, the eCoin features minimal surgical trauma, a low complication rate, and high patient acceptance, having accumulated extensive clinical experience over many years on the market.
eCoin System
Approximately 30 million Americans aged 40 and olderUpperOveractive Bladder (OAB）Patients have long faced therapeutic dilemmas. Although traditional sacral nerve stimulation is effective, few patients are willing to undergo this therapy due to its surgical complexity, invasive nature, and high risk of complications.
The advent of eCoin has pioneered a new, safer, and more convenient track for ITNS therapy, with its clinical advantages already validated. Through this acquisition, Boston Scientific has achieved the following strategic breakthroughs:
Rapidly enter the fast-growing ITNS market, complementing the existing Axonics product portfolio
Developing a Comprehensive Disease Management Solution, Covering the Full Treatment Spectrum from Conservative Therapies to Neuromodulation
Seize the market initiative to counter competitive pressures from Medtronic and other rivals
The transaction is expected to be completed in the first half of 2026, with a neutral impact on adjusted earnings per share for the year and a controllable dilutive effect under GAAP.
Meghan Scanlon, President of Boston Scientific’s Urology division, stated, “The addition of eCoin will drive our expansion into the high-growth ITNS sector. Its technology creates synergies with our existing pelvic health product portfolio, ultimately enabling us to provide patients with more comprehensive whole-disease-course treatment solutions.”
Overactive bladder (OAB) profoundly impacts patients’ quality of life, affecting multiple dimensions including mental health, sleep, and work productivity. While conventional treatments are limited by efficacy constraints or excessive invasiveness, neuromodulation therapy is emerging as a mainstream approach. This acquisition will further strengthen Boston Scientific’s leadership position in urology.
The content of this article is for reference only and does not constitute investment advice. Readers are advised to exercise due diligence in evaluating the information.If any platform republishes this article, it shall bear sole responsibility for such republication. Medical Device Business Review shall not be held liable for any secondary dissemination effects arising therefrom.
Year-End Limited-Time Special Offer: ¥269!Click the image to purchase directly
If you find the content rewarding, please feel free to★、Like、Forward！
Your Support Is Our Greatest Motivation
